We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Sites of AIDS Clinical Trials Units Announced

By HospiMedica staff writers
Posted on 19 Mar 2007
The first group of 60 human immunodeficiency (HIV)/AIDS Clinical Trials Units (CTUs) will be carried out by the [U.S.] National Institute of Allergy and Infectious Diseases (NIAID, Bethesda, MD, USA).

These CTUs (and an additional 13 to be named at a later date) have been established to carry out the next generation of HIV/AIDS vaccine, prevention, and treatment research. More...
To this end, NIAID has earmarked US$285 million. This figure includes funding for previously existing CTUs and clinical research sites to continue their participation in ongoing studies for a period to ensure that there are no gaps in current HIV/AIDS research studies. Each CTU will be led by a principal investigator and include an administrative component, community advisory board, and one or more clinical research sites. CTUs will be located in the following US states and territories: Alabama, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Washington DC, and Puerto Rico. Additional CTUs are expected in Louisiana and Washington, D.C.
The CTUs located outside of the US are in the following countries: the Dominican Republic, Haiti, Jamaica, Peru, South Africa and Switzerland. Additional CTUs are anticipated in Brazil, China, France, India, and Thailand.

"These Clinical Trials Units will work with our clinical research networks in a flexible, collaborative, and coordinated way to tackle the critical research questions that can help accelerate progress against the HIV/AIDS pandemic,” said Dr. Anthony S. Fauci, director of NIAID.


Related Links:
National Institute of Allergy and Infectious Diseases

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.